Brii Biosciences Limited
BRIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 7,993.4% | -98.8% | -44.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | -808.7% | -88,217.3% | -995.3% | -659.7% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$4 |
| Pre-Tax Income | -$1 | -$0 | -$0 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$0 | -$0 | -$4 |
| % Margin | -1,017.6% | -28,335.3% | -938.1% | -4,452.3% |
| EPS | -0.7 | -0.24 | -0.67 | -9.48 |
| % Growth | -191.7% | 64.2% | 92.9% | – |
| EPS Diluted | -0.7 | -0.24 | -0.67 | -9.48 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$1 | -$1 |
| % Margin | -804.2% | -27,261.3% | -975.4% | -651.4% |